Physician profile
Annis Marney
NPI 1437206315
$26,024.45
in general payments reported to CMS, 2019-2025
64 companies · $3,852 in 2025
The $3,852 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,626 · 2020: $2,833 · 2021: $3,518 · 2022: $3,860 · 2023: $4,376 · 2024: $3,959 · 2025: $3,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,187.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,499.89 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $3,083.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $2,230.09 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $1,951.29 | 2019-2025 | Repatha, Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $1,079.74 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,039.15 | 2019-2025 | Jardiance, Synjardy |
| Corcept Therapeutics | $929.82 | 2019-2024 | Korlym |
| Insulet Corporation | $895.38 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $861.19 | 2020-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Sanofi-Aventis U.S. LLC | $855.34 | 2019-2025 | |
| Mannkind Corporation | $679.35 | 2019-2024 | Afrezza |
| Beta Bionics, INC. | $659.24 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ibsa Pharma INC. | $620.90 | 2020-2025 | Tirosint, Tirosint, Licart |
| Cequr Corporation | $508.59 | 2023-2025 | Cequr Simplicity |
| Abbvie INC. | $455.99 | 2019-2025 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $417.87 | 2020-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $364.80 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Ultragenyx Pharmaceutical INC. | $359.43 | 2019-2023 | |
| Tandem Diabetes Care, INC. | $357.85 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $323.38 | 2019-2025 | |
| Ascensia Diabetes Care US INC. | $270.46 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $249.88 | 2019-2022 | |
| Radius Health, INC. | $242.17 | 2019-2025 | Tymlos |
| Chiesi USA, INC. | $225.96 | 2025 | Mycapssa |
| Valeritas, INC. | $222.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.16 | 2021-2025 | |
| Zealand Pharma US, INC. | $207.86 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $192.04 | 2019-2025 | Strensiq |
| Horizon Therapeutics Plc | $191.35 | 2019-2023 | Tepezza |
| Averitas Pharma INC. | $176.23 | 2024-2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.71 | 2019-2023 | Cycloset |
| Sequel Med Tech, LLC | $163.79 | 2025 | Twiist |
| Esperion Therapeutics, INC. | $154.31 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $150.54 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $148.43 | 2023-2025 | Yorvipath |
| Shire North American Group INC | $145.92 | 2019 | |
| Medtronic Minimed, INC. | $132.11 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $114.16 | 2022-2024 | |
| Kyowa Kirin, INC. | $113.12 | 2022-2023 | Crysvita |
| Antares Pharma, INC. | $112.56 | 2021-2022 | |
| Companion Medical, INC. | $111.46 | 2019-2020 | |
| Clarus Therapeutics INC. | $100.98 | 2021 | |
| Lifescan, INC. | $88.41 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $82.86 | 2021-2025 | Unithroid |
| Takeda Pharmaceuticals U.S.A., INC. | $77.58 | 2020 | |
| Recordati_rare_diseases_inc. | $74.13 | 2023-2024 | Signifor Lar, Isturisa |
| Regeneron Healthcare Solutions, INC. | $69.84 | 2019 | |
| Nestle Healthcare Nutrition INC. | $65.57 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $62.59 | 2024-2025 | |
| Amryt Pharma Holdings LTD | $59.27 | 2023 | Mycapssa |
| Verity Pharmaceuticals INC. | $52.63 | 2024 | Tlando |
| Ipsen Biopharmaceuticals, INC | $48.94 | 2019-2023 | Somatuline Depot |
| Madrigal Pharmaceuticals | $46.88 | 2025 | Rezdiffra |
| Nevro Corp. | $45.79 | 2023-2024 | Senza |
| Rhythm Pharmaceuticals, INC. | $44.99 | 2023-2025 | Imcivree, Imcivree |
| Amarin Pharma, INC. | $42.89 | 2021 | |
| Tolmar, INC. | $42.40 | 2024 | |
| Astellas Pharma US INC | $38.75 | 2023-2025 | Veozah |
| Senseonics, Incorporated | $26.00 | 2019 | |
| Halozyme INC | $15.81 | 2023 | |
| Sanofi US Services INC. | $15.08 | 2025 | |
| Bigfoot Biomedical INC | $14.28 | 2023 | Unity Diabetes Management System |
| Eisai INC. | $13.69 | 2019 | |
| Glaxosmithkline, LLC. | $13.48 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annis Marney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.